


Supplementary Table 1: Full breakdown of incremental costs and savings accrued through 100% detection of high risk conditions compared with current detection rates.


Cost Type	5 year horizon		10 year horizon		25 year horizon	
	Current Care Management	NICE Guidelines Management	Current Care Management	NICE Guidelines Management	Current Care Management	NICE Guidelines Management
NHS Health Check	-£144,376,123	-£144,454,003	-£322,491,679	-£322,643,893	-£732,764,173	-£732,434,911
Annual review	£602,276,074	£605,491,005	£1,369,037,876	£1,379,781,496	£2,901,286,454	£2,936,782,840
Cascade testing	£119,826,201	£111,981,226	£113,180,304	£101,291,878	£85,953,009	£59,352,492
Diagnosis of high risk conditions	£606,697,648	£611,911,742	£704,511,159	£717,303,972	£850,149,925	£860,746,098
Lipid modification drugs	£511,151,801	£1,127,506,481	£992,762,563	£2,129,090,944	£2,085,066,266	£4,371,984,606
Antihypertensive therapy	£631,756,048	£1,895,406,902	£1,184,244,247	£3,518,351,414	£2,380,558,738	£6,981,700,166
Anticoagulant treatment	£1,433,393,404	£3,098,951,654	£3,036,917,969	£6,651,632,293	£7,814,743,092	£16,987,987,031
Type 2 diabetes treatment	£599,197,508	£1,463,632,451	£1,645,134,209	£4,238,851,475	£3,235,499,596	£12,927,109,504
NHS DPP	£2,217,741,775	£3,138,779,179	£3,160,490,079	£3,922,981,431	£3,970,897,181	£4,638,102,810
Structured diabetes education	£35,665,193	£528,976,520	£62,799,377	£588,303,406	£128,106,445	£725,059,954
Behavioural weight management	£218,353,573	£816,060,941	£344,090,023	£840,982,725	£403,925,952	£787,807,972
Smoking cessation	£60,328,077	£2,571,941,214	£120,118,580	£4,493,321,154	£226,347,677	£7,170,740,243
Nutritional advice for CKD	£65,157,603	£199,967,605	£90,624,702	£216,284,440	£131,553,965	£266,844,158
Medicine use review	£208,012,747	£552,798,785	£279,954,223	£690,198,201	£462,629,096	£973,908,461
Blood pressure self-monitoring	£238,666,230	£3,333,432,625	£455,160,004	£6,209,404,273	£935,477,237	£12,451,838,338
Insulin pump	£149,660	£958,320,952	£567,338	£1,696,312,917	£1,941,460	£3,038,246,765
Cardiovascular disease	-£5,388,183,314	-£13,534,015,801	-£14,951,758,314	-£32,515,646,758	-£66,923,620,828	-£111,165,989,435
End stage renal failure	£35,337,490	£130,410,773	£154,608,312	£488,284,754	£709,468,899	£1,415,354,059

Blindness	-£91,248,963	-£241,532,808	-£458,490,411	-£738,629,293	-£7,689,844,535	-£8,378,541,124
Ulcer and amputation	£110,486,327	-£60,921,924	£53,051,244	-£234,728,422	-£23,681,844,282	-£24,271,886,435
Breast and bowel cancer	£2,570,669	-£2,670,172	£14,632,237	£32,329,829	£137,424,611	£235,989,499
Osteoarthritis	-£40,959,960	-£166,406,853	-£125,465,180	-£265,254,854	£260,862,088	£631,692,049
Depression	£113,970,023	£74,112,787	£357,201,948	£340,506,744	£1,675,870,134	£2,153,720,436
Dementia	£202,148	£580,482	£193,966	£590,903	£350,425	£835,110
Major bleed	£42,687,131	£91,223,570	£104,519,742	£224,229,864	£360,967,382	£736,828,971

Supplementary Figure 1: Distribution of PSA samples on the cost-effectiveness plane for 100% detection of all high risk conditions at the 25-year time horizon: current levels of management (blue) and NICE guideline levels of management (orange) vs current care. Mean values are shown by large diamonds. The cost-effectiveness threshold is assumed to be £20,000 per QALY



Supplementary Figure 2: Trajectories showing the accumulation of incremental costs, savings and health benefits over the 25-year horizon under two scenarios for 100% detection of each high risk condition: current levels of management (left) or NICE guideline levels of management (right).



Supplementary Figure 3: Distribution of PSA samples on the cost-effectiveness plane for 100% detection of each high risk condition compared to current care, under two different management scenarios at the 25-year time horizon: current levels of management (top) and NICE levels of management (bottom). Mean values are shown by large diamonds. The cost-effectiveness threshold is assumed to be £20,000 per QALY.

